Drug intelligence / Profile preview

BSC2201

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BSC2201 is a preclinical-stage small molecule inhibitor of ALK5 (Transforming Growth Factor-beta receptor type 1, TGFBR1) being developed by BiSiChem. It is specifically designed to serve as a payload for antibody-drug conjugates (ADCs) targeting solid cancers. By inhibiting ALK5, the drug aims to disrupt the TGF-beta signaling pathway, which is frequently implicated in tumor growth, metastasis, and the creation of an immunosuppressive tumor microenvironment. The use of BSC2201 as an ADC payload allows for the targeted delivery of this TGF-beta signaling inhibitor directly to cancer cells, potentially enhancing efficacy while minimizing systemic toxicity.

Targets

TGFBR1

Beyond the preview

Go deeper on BSC2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC2201.

Explore the full profile